Comparison
AOD-9604 vs. BPC-157
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Healing
CAS no.
221231-10-3
137525-51-0
Molecular weight
1815.09 g/mol
1419.5 g/mol
Half-life
0.4 h
4 h
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheGEPPPGKPADDAGLVMechanism of action
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
3
4
of which in humans
2
0
Effects recorded
3
4
Open conflicts
1
2
Documented adverse events
1
2